research in resource- limited settings

\1
THE ANRS &
research
in resourcelimited
settings
/
2
THE ANRS &
research
in resourcelimited
settings
\3
untries and the develop
4
resource-limited co
The ANRS: commited to
4
Funding of research pro
5
earch betwee
ership at the heart of res
rtn
pa
a
:
es
sit
RS
AN
e
Th
ted countries
world and resource-limi
6
Managing research in res
6
rch in res
The main lines of resea
7
Ethics and good research
posals
ource-limited countries
ource-limited countries
practice
rce-limi
ANRS “Research in resou
7
8
Bibliographic references
12
Map of partner countries
14
The ANRS sites
14
16
18
20
22
24
26
28
30
ed world
The Burkina Faso site
The Cameroon site
The Côte d’Ivoire site
The Senegal site
The Cambodia site
The Vietnam site
The Egypt site
The Brazil site
Ongoing projects
ted settings” departmen
t
n the developed
/
4
The ANRS: commited to the
resource-limited countries and
the developed world
n
Since 1992, the Research Agency ANRS (France Recherche Nord&Sud
Sida-HIV Hépatites) has been executing, coordinating and funding
research on HIV/AIDS and, since 2003, on viral hepatitis, in France and
in countries with limited resources. Its annual budget, comprising
mainly public funding, amounts to approximately 44 million euros.
Annual budget of the
ANRS: approximately
44 million euros
1992
✔
Creation of the French
Agency for AIDS Research
1999
n Despite the progress made in the fight against these two epidemics,
UNAIDS estimates that approximately 35 million adults and children
around the world are infected by the AIDS virus. More than 240 million
people are infected by the hepatitis B virus and 184 million by the
hepatitis C virus. This is a global public health problem that spares
neither the developed world nor resource-limited countries. This is
why the ANRS supports research in both the developed world and in
resource-limited settings and every year earmarks over 20% of its
budget for countries with limited resources.
Funding of research proposals
n
✔ ANRS calls for research
Two annual calls for research proposals (January and June) are
open to all public or private research laboratories, whatever their
field of research.
proposals open to resourcelimited countries
n
✔ First proposal funded:
ANRS DITRAME PLUS-13
2003
✔ ANRS scope extended
to viral hepatitis
2012
✔
The ANRS became an
autonomous agency of Inserm
Proposals for research in countries with limited resources must
include at least one French team and one relevant team from the
country or countries where the research will be conducted.
n Proposals are reviewed by an ANRS independent and multidisciplinary scientific committee (CSS6) comprising 15 French and foreign researchers and clinicians from the developed world and from
resource-limited settings1. Representatives of patient groups from
resource-limited settings and the developed world are also voting
members.
n Between 2011 and 2013, on average, 30% of proposals submitted
to the ANRS were funded2.
2e APP
APPEL
PEL À PRO
PROJETS
OJETS
TS 2014
14
P
ROJETS D
E RECHERCHE, CONTRA
’INITIA
’UNE RECHERCHE,
PROJETS
DE
CONTRATS
NTRA
ATS
TS D
D’INITIATION
IA
ATION D
D’UNE
A
LLOCA
ATIONS D
E RECHERCHE, COLLOQ
UES ET P
UBLICA
ATIONS
ALLOCATIONS
DE
COLLOQUES
PUBLICATIONS
2013
✔
A new identity for
the ANRS and a new logo
DOMAINES
DOMAINE
S DE
DE RECHERCHE
ERCHE :
ENSEMBLE D
DES
ES RECHERCHES S
SUR
UR LE V
VIH/SIDA
IH/SIDA ;
RECHERCHES S
SUR
UR D
D’AUTRES
’AUTRES THÉMA
THÉMATIQUES
TIQ
TIQ
I UES D
DÈS
ÈS LORS Q
QU’ELLES
U’ELLES SONT U
UTILES
TILES
DE
PHYSIOPATHOLOGIE
DE
PAR
À LA COMPRÉHENSION D
E LA PHYSIOP
ATTHOLOGIE
OLOGIE D
E LL’INFECTION
’INFECTION
INFECTION P
A
AR LE VIH.
VIH.
H
ENSEMBLE DES
DES RECHERCHES SUR
SUR LES V
HÉPATITES
É ATITES
IRUS D
ES HÉPA
ENSEMBLE
VIRUS
DES
VIH/HÉPA
ATITES.
ET LES CO-INFECTIONS VIH/HÉPATITES.
INFORMATIONS
INFORMA
ATIONS ET FORMULAIRES
FORMULAIRES SUR
SUR www
www.anrs.fr
.anrs.fr
s.frr
Utiliser impérativement
les formulaires du 2e appel à projets 2014
L’appel à projets est ouver
ouvertt à tout laboratoire de rec
recherche,
herche, public ou pri
privé
vé
1. Proposals concerning cohort follow-up
studies are reviewed by a specific evaluation
committee.
2. The complete list of ongoing projects funded
by the ANRS can be found on pages 30 to 35.
3. ANRS DITRAME PLUS-1. Evaluation of
peripartum interventions in prevention of
mother-to-child HIV transmission in Africa.
\5
The ANRS sites: a partnership at the
heart of research between the
developed world and resource-limited
countries
Africa,
Southeast
Asia, Egypt,
and Brazil
n The Research Agency ANRS (France Recherche Nord&Sud SidaHIV Hépatites) concentrates its human and financial resources in
its “country sites4”:
– in Africa: Côte d’Ivoire, Senegal, Burkina Faso, Cameroon
– in Southeast Asia: Vietnam and Cambodia
– Egypt
– Brazil.
n
In partnership with national health and research authorities, the
ANRS sites5 are placed under the joint responsibility of a coordinator
from the developed world and a coordinator from a resource-limited
country who in collaboration define the key lines of research. The
ANRS sites facilitate the establishment of research programs
between:
– national institutions of the partner countries (university hospitals,
laboratories and research centers, local Institut Pasteur, national
AIDS programs…),
– French research organizations like the Research Development
Institute (IRD), the National Institute of Health and Medical Research
(Inserm), the National Center for Scientific Research (CNRS), the
Institut Pasteur network, universities, the Network for Therapeutic
Solidarity in Hospitals (Esther)…,
– institutions in other countries (National Institutes of Health, Centers
for Disease Control, United States, London School of Hygiene and
Tropical Medicine, United Kingdom…),
- international institutions (World Health Organization, European &
Developing Countries Clinical Trials Partnership…).
Sustained
support
in personnel,
equipment,
and buildings
n ANRS provides its sites with sustained support in personnel,
laboratory equipment, and buildings.
n
Scientific days are held regularly at each site. They offer an opportunity for ANRS managers and researchers, clinicians, civil society
representatives, national authorities, and the press, to discuss how
projects are moving forward, the results obtained, and future perspectives.
n
About 70% of the budget that the ANRS allocates to countries with
limited resources is earmarked for research at the sites, 30% being
allotted to projects conducted “off-site”, mainly in Africa.
4. Map of sites, pages 12-13.
5. Site activities, pages 14 to 29.
/
6
Managing research in resourcelimited countries
Defining
emerging
research
areas
n The Research Agency ANRS (France Recherche Nord&Sud Sida-HIV
Hépatites) coordinated action "Research in resource-limited countries" (AC12) covers scientific and strategic research in these countries 6.
n
AC12, which comprises coordinators from the developed world and
from ANRS sites and experts in various fields, defines emerging
areas of research.
n
Several multidisciplinary working groups draw up proposals in these
areas and support the creation of networks between countries with
limited resources.
The main lines of research in
resource-limited countries
Antiretrovirals for adults: early treatment of adults, management
of patients in whom first and second-line antiretroviral treatment
has failed, evaluation of WHO recommendations, prevention and
treatment of opportunistic infections (cryptococcosis…).
Tuberculosis and HIV co-infections: search for the best therapeutic
strategies using combinations of antiretrovirals and tuberculosis
drugs, prevention of tuberculosis in HIV-positive patients.
Prevention of mother-to-child HIV transmission and pediatric
research: transmission of HIV in breast milk and early treatment of
the child, comparison of treatment regimens in children, long-term
effect of antiretrovirals.
Viral resistance in countries with limited resources: collaboration with
the WHO in national programs on monitoring resistance in untreated
subjects and in patients on antiretrovirals.
Supporting
the creation of
networks between
resource-limited
countries
Alternative techniques in virology: development and quality control
of low-cost virological tests.
Prevention of sexual transmission of HIV: clinical and social sciences
research on prevention, mostly in the biomedical field (circumcision,
peri-exposure prophylaxis, treatment as prevention…).
Social sciences and health economics research: screening and
access to healthcare, experience of living with the disease, public
epidemic control policy, drug policy, pharmaceutical market…
Hepatitis: hepatitis C and hepatitis B-HIV co-infections, prevention of
HIV infection and viral hepatitis in drug users.
7. President of the AC12: François Dabis,
Inserm U897, Université Victor Segalen,
Bordeaux
\7
Ethics and good research preactice
Since 2002, the ANRS has a charter of ethics and good research practice
which is applied in countries with limited resources and serves as the
reference for all researchers seeking to conduct an ANRS-funded
project in such countries . The key principles of the ANRS “Ethics
Charter” for research in developing countries” are as follows:
The notion of partnership between the developed world and
resource-limited countries in all fields: composition of committees
(evaluation committee, working groups) and teams responsible for
research, collaboration with national public health programs on the
definition of research priorities, delivery of results in the corresponding
country.
Protection of human research participants. ANRS assumes its
responsibilities as sponsor and has taken out a civil liability insurance
to cover all patients participating in biomedical research. An
independent monitoring committee evaluates the adherence to ethical
principles during research, the application of good practice guidelines,
and the validity of certain results.
The ANRS ensures medical management of patients throughout
the research and a commitment by the national authorities is required
for follow-up treatment after every trial.
The increased role of viral hepatitis research and changes in resourcelimited settings in terms of the ethics of research and the protection
of participants are such, that the ANRS anticipates a revision of its
charter in the medium term.
To ensure
that the optimal
conditions for the
implementation
of research
are respected
ANRS “Research in resource-limited
settings” department
A team of six people oversees: the science policy and general
strategy for all research conducted in resource-limited settings, the
organization and implementation of the research projects, the
coordination of activities, and the management of the sites. It also
provides scientific and administrative support for the research teams.
2008 2008
November
November
7. The ethics charter covering research
in developing countries (2008 update)
is available on the ANRS website:
http://www.anrs.fr/HIV-SIDA/Pays-endeveloppement/Presentation-generale.
Contact : Brigitte Bazin
Director of the “Research
in resource-limited settings”
department
Tél. : + 33 (0) 1 53 94 60 13
[email protected]
charter
charter
Ethics
Ethics
countries
countries
in developing
in developing
for research
for research
0 A0 Y2 2A 0N 0D 2 A AMNE DN DAEMDE NO DC ET DO BOE CR T O2 B0 E0 R8 2 0 0 8
EN
W R I T TW
T TAEYN 2M
RIM
I
GENERALI PRINCIPLES
GENERAL PRINCIPLES
texts R pageto4texts R page 4
1.1 Adherence
1.1 toAdherence
1.2
1.3
page 5
populations
R page 5
health ofthe
theimproving
health of Rpopulations
A top priority:
top priority:
1.2 A improving
page 5
cooperation
R page 5
Partnership
and Rcooperation
Partnership
1.3 and
/
8
Preventive treatment
1999
Cotrimoxazole prophylaxis of
opportunistic infections at the first
stages of HIV infection
Early chemoprophylaxis with trimethoprim-sulphamethoxazole
for HIV-1-infected adults in Abidjan, Cote d’Ivoire: a randomized
trial. Cotrimo-CI Study Group. Anglaret X, Chene G, Attia A,
Toure S, Lafont S, Combe P, Manlan K, N’Dri-Yoman T,
Salamon R. Lancet 1999; 353 (9163); 1463-1468 (ANRS 059)
Bibliographic
references
Origin of the virus
2001
The history of transmission
of HIV-1
Dating the common ancestor of SIVcpz and HIV-1 group M and
the origin of HIV-1 subtypes using a new method to uncover
clock-like molecular evolution. Salemi M, Strimmer K, Hall
WW, Duffy M, Delaporte E, Mboup S, Peeters M, Vandamme
AM. FASEB J. 2001 ; 15 (2) : 276-278. Epub 2000 Dec 8.
Treatments
2004
Efficacy of a generic combination
for first-line treatment in Africa
Effectiveness and safety of a generic fixed-dose combination
of nevirapine, stavudine, and lamivudine in HIV-1-infected
adults in Cameroon : open-label multicentre trial. Laurent
C, Kouanfack C, Koulla-Shiro S, Delaporte E, for the ANRS 1274
study group (2004). The Lancet 2004; 364 (9428): 29-34 (ANRS
1274)
Biomedical prevention
2005
Male circumcision greatly reduces
(60%) the risk of HIV transmission
to men
Randomized, Controlled Intervention Trial of Male Circumcision
for Reduction of HIV Infection Risk: The ANRS 1265 Trial. Auvert
B, Taljaard D, Lagarde E, Sobngwi-Tambekou J, Sitta R, et al.
PLoS Med. 2005 ; 2 (11) : e298 (ANRS 1265)
\9
Mother-to-child transmission
2005
Short zidovudine treatment and
single-dose nevirapine effectively
reduce mother-to-child HIV
transmission
Origin of the virus
Field efficacy of zidovudine, lamivudine and single-dose
nevirapine to prevent peripartum HIV transmission. Dabis F,
2006
Bequet L, Koumavi Ekouevi D, Leroy V. AIDS 2005 ; 19 (3) : 309318 (DITRAME ANRS 1201)
The gorilla (DRC) is the natural
reservoir of HIV-1 group O
Human immunodeficiency viruses : SIV infection in wild
gorillas. Van Heuverswyn F, Li Y, Neel C, Peeters M. Nature
2006 ; 444 (7116) : 164 (ANRS 12125)
Origin of the virus
2006
The chimpanzee subspecies Pan
troglodytes troglodytes
(Cameroon) is the natural
reservoir of HIV-1 strains M and N
Treatments
2007
Chimpanzee Reservoirs of Pandemic and Nonpandemic
HIV-1. B F Keele, Van Heuverswyn F, Li Y, Peeters M and H
Hahn B. Science 2006 ; 313 (5786) : 523-526
Valaciclovir reduces genital viral
load of HIV-1 in women with HIV1/HSV-2 co-infection
Reduction of HIV-1 RNA Levels with Therapy to Suppress
Herpes Simplex Virus. Nagot N, M.D., Ouédraogo A,
Foulongne V, Van de Perre P, Mayaud P, for the ANRS 1285
Study Group. N Engl J Med. 2007 ; 356 : 790-799 (ANRS 1285)
Treatments
2011
Efficacy of early antiretroviral
treatment of patients co-infected
with HIV and tuberculosis
Earlier versus later start of antiretroviral therapy in
HIVinfected adults with tuberculosis. Blanc FX, Sok T,
Laureillard D, Borand L, Goldfeld AE. N Engl J Med. 2011 ; 365
(16) : 1471-1481 (ANRS 1295)
/
10
Management
2012
Clinical monitoring alone versus
monitoring of viral load and CD4
cell counts in Cameroon
Mother-to-child transmission
2011
Efficacy of triple antiretroviral
therapy in reducing the risk of
mother-to-child transmission
Triple antiretroviral compared with zidovudine and singledose
nevirapine prophylaxis during pregnancy and breastfeeding
for prevention of mother-to-child transmission of HIV-1 (Kesho
Bora study) : a randomised controlled trial. The Kesho Bora
Study Group. Lancet Infect Dis. 2011 ; 11 (3) ; 171-180. (ANRS
1289 Kesho Bora)
Monitoring of HIV viral loads, CD4 cell counts, and clinical
assessments versus clinical monitoring alone for antiretroviral
therapy in rural district hospitals in Cameroon (Stratall ANRS
12110/ESTHER) : a randomised non-inferiority trial. Laurent
C, Kouanfack C, Laborde-Balen G, Aghokeng AF, Mbougua JB,
Boyer S, Carrieri MP, Mben JM, Dontsop M, Kaze S, Molinari N,
Bourgeois A, Mpoudi-Ngole E, Spire B, Koulla-Shiro S,
Delaporte E. Lancet Infect Dis. 2012; 11 (11); 825-833 (ANRS
12110 STRATALL)
HIV/tuberculosis co-infection
2012
Association between natural killer
cell degranulation and risk of
immune reconstitution inflammatory
syndrome in patients co-infected
with HIV and tuberculosis
Management
2012
Morbidity and mortality of patients
before initiating ARV treatment,
stratified by CD4 counts
AIDS and non-AIDS morbidity and mortality across the
spectrum of CD4 cell counts in HIV-infected adults before
starting antiretroviral therapy in Cote d’Ivoire. Anglaret X,
Minga A, Gabillard D, Ouassa T, Messou E, Morris B, Traore M,
Coulibaly A, Freedberg KA, Lewden C, Menan H, Abo Y, DakouryDogbo N, Toure S, Seyler C. Clin Infect Dis. 2012 ; 54 (5) : 714723 (ANRS 12222 Morbidity/Mortality STU)
Natural killer cell degranulation capacity predicts early
onset of the immune reconstitution inflammatory
syndrome (IRIS) in HIV-infected patients with tuberculosis.
Pean P, Nerrienet E, Madec Y, Borand L, Laureillard D,
Fernandez M, Marcy O, Sarin C, Phon K, Taylor S, Pancino G,
Barré-Sinoussi F, Scott-Algara D. Blood 2012 ; 119 (14) ; 33153320 (ANRS 1295 CAMELIA)
Treatments
2013
Use of nevirapine as an
alternative to efavirenz in patients
co-infected with HIV and
tuberculosis
Nevirapine versus efavirenz for patients co-infected with HIV
and tuberculosis : a randomised non-inferiority trial. Bonnet M,
Bhatt N, et al. (ANRS 12146 CARINEMO). Lancet Infect Dis.
2013 ; 13 (4) ; 303-312.
\11
2008
The Political Economy of HIV/AIDS in Developing Countries.
Trips, public Health Systems and Free Access. Benjamin Coriat
(Edited by), Edward Elgar Publishing Ltd, 2008, 384 p.
Reference
works
on social
sciences
research
2/03/10
10:09
Page 1
Collection Sciences sociales et sida
2010
Accès décentralisé au traitement du VIH/sida. Évaluation
de l’expérience camerounaise. Fred Eboko, Claude Abé,
Christian Laurent. ANRS, Collection Sciences sociales et sida,
2010, 324 p.
2011
Les femmes à l’épreuve du VIH dans les pays du Sud. Genre
et accès universel à la prise en charge. Alice Desclaux, Philippe
Msellati, Khoudia Sow. ANRS, Collection Sciences sociales et
sida, 2011, 555 p.
[
more at www.anrs.fr
Accès
décentralisé
au traitement
du VIH/sida
Évaluation de
l’expérience
camerounaise
Sous la direction de
Fred Eboko
Claude Abé
Christian Laurent
Collection Sciences sociales et sida
Les femmes
à l’épreuve
du VIH dans
les pays du Sud
Genre et
accès universel
à la prise en
charge
Sous la direction de
Alice Desclaux
Philippe Msellati
Khoudia Sow
]
Collection Sciences sociales et sida
2012
From collaborative research to community-based research. A
methodological toolkit. Élise Demange, Émilie Henry, Marie
Préau. ANRS, Collection Sciences sociales et sida, 2012, 211 p.
2013
These publications can be accessed on the
ANRS website:
http://www.anrs.fr/ressources-etpublications/publications/publications-ANRS
Accès aux antirétroviraux dans les pays du Sud. Propriété
intellectuelle et politiques publiques. Cristina Possas, Bernard
Larouzé. ANRS, Collection Sciences sociales et sida, 2013,
272 p.
From collaborative
research
to community-based
research
A methodological toolkit
Elise Demange
Emilie Henry
Marie Préau
/
12
Partner countries
Canada
Norway
United Kingdom
Belgium
France
United States
Morocco
Dominican Republic
Mali
Senegal
Burkina Faso
Guinea
Côte d’Ivoire
Togo
Suriname
Republic of
Brazil
Partner countries-sites in resource-limited settings
Partner countries in resource-limited settings
Partner countries in the developed world
\13
n
Concentration of means at 8 country sites
n One third of the budget for limited-resource settings devoted
to 19 other countries
n Collaboration with 9 countries in the developed world
Germany
Luxembourg
Switzerland
Georgia
Egypt
India
Laos
Vietnam
Cambodia
Cameroun
Central African Republic
Democratic Republic
of Congo
Uganda
Gabon
Burundi
the Congo
Zambia
Malawi
Madagascar
South Africa
/
14
Burkina
Faso SITE
The Muraz Center at
Bobo-Dioulasso.
The site
The site was created in 1994. Historically, it was structured around
the Muraz Center, a multidisciplinary research facility that became
a Burkina Faso public institution in 2001 (HIV/AIDS, malaria,
tuberculosis).
In this setting, the Research Agency ANRS (France Recherche
Nord&Sud Sida-HIV Hépatites) provided the Muraz Center with
equipment and with reception facilities for the recruitment and followup of cohorts, a molecular virology laboratory (biosafety level 2), and
an immunology laboratory. A computing, methodological and
statistical (IT center) resources center was built there by the ANRS
and inaugurated in 2004.
A second research center was developed at Ouagadougou in the
Health Sciences Faculty, at the International Health Research Center
of the University of Ouagadougou.
Areas of research
Above, the Charles-deGaulle Hospital in
Ouagadougou.
Below, the Internal
Medicine Department of
the Yalgado Ouédraogo
Hospital in
Ouagadougou.
The main area of research at the site is the prevention and treatment
of HIV infection in women and children. Since its creation, the site
has developed clinical research programs comprising clinical trials
on prevention of mother-to-child HIV transmission (particularly through
breastfeeding) and antiretroviral treatment of children. Social sciences
and public health research relates to anthropological analysis of
clinical trials, how children experience the disease and how it is
treated, and to the study of the social and economic conditions of
access to healthcare for women living with AIDS. Lastly, laboratory
research is being conducted on the immunological and virological
determinants of HIV transmission (sexual and mother-to-child),
resistance to antiretrovirals, and the impact of HIV/tuberculosis coinfection on the dynamics of the HIV epidemic.
Between 1998 and 2010, studies of a cohort of vulnerable women
(Cohort Yerelon-ANRS 1222) yielded various publications and enabled
investigation of the immunological and virological mechanisms of
viral interactions, notably between HIV and the herpes virus.
Also, a program on viral hepatitis is under way consisting of the followup of a cohort of children infected by hepatitis B virus, using a realtime in-house PCR method to detect and quantify hepatitis B viral
DNA in serum.
\15
PARTNERS IN BURKINA FASO
n
n
n
n
n
n
n
n
n
Centre hospitalier universitaire pédiatrique Charles-de-Gaulle
de Ouagadougou
Centre hospitalier universitaire Yalgado Ouédraogo de Ouagadougou
Comité ministériel de lutte contre le sida du secteur santé (CMLS/Santé)
Conseil national de lutte contre le sida (CNLS-IST)
Direction régionale de la Santé du Centre à Ouagadougou
Direction de la Santé de la famille (DSF) du ministère de la Santé
Groupe de recherche action en santé (GRAS)
Université de Ouagadougou
Université de Ouagadougou, unité de formation et de recherche en sciences
de la santé (UFR-SDS)
PARTNERS IN FRANCE AND IN EUROPE
n
n
n
n
n
n
n
n
n
n
n
n
Centre hospitalier universitaire Arnaud de Villeneuve, Montpellier
Centre hospitalier universitaire du Luxembourg, CRP-Santé, Luxembourg
Faculté de médecine Paris-Descartes
GIP Esther (Ensemble pour une solidarité thérapeutique hospitalière en réseau)
Hôpital Cochin, Paris
Hôpital Necker, Paris
Hôpital universitaire des enfants de la reine Fabiola, Belgique
Institut de médecine tropicale d’Anvers, Belgique
Institut national de la santé et de la recherche médicale (Inserm)
Institut Pasteur
Institut de recherche pour le développement (Ird)
Université Montpellier 1
Developed world coordinator
Pr PHILIPPE VAN DE PERRE
Inserm U1058 « Infection par le VIH et par agents
à tropisme cutanéo-muqueux : de la pathogénèse à la prévention »
Département de bactériologie-virologie
CHU Arnaud de Villeneuve
371, avenue du doyen Gaston-Giraud
34295 Montpellier cedex 5 – France
p-van_de_perre @ chu-montpellier.fr
Resource-limited setting coordinator
Pr NICOLAS MEDA
Centre Muraz/Ministère de la Santé
2054, avenue Mamadou Konate
01 BP 390 Bobo-Dioulasso 01 – Burkina Faso
nmeda.muraz @ fasonet.bf
UFR Sciences de la Santé
CRIS/Site ANRS Burkina – Université de Ouagadougou
09 BP 168 Ouagadougou 09 – Burkina Faso
nicolas.meda @ univ-ouaga.bf
/
16
Cameroon
SITE
Opposite, the ANRS
site, Yaounde Central
Hospital.
Below, a view of
Yaounde.
The site
Historically, the site was set up through a strong partnership
developed by the « Centre IRD de Montpellier ». Collaborations
between Cameroonian and French teams started in 1999 through the
creation of a research site set up and equipped by the Research Agency
ANRS (France Recherche Nord&Sud Sida-HIV Hépatites) on the
grounds of the Yaounde Central Hospital. This collaboration was
formalized in 2005 by a tripartite agreement between the Cameroonian
Health and Research Ministries and the ANRS. The Centre Pasteur
of Cameroon is an essential partner in research conducted at the site.
Areas of research
Research currently under way at the site relating to HIV infection:
virology (origin and transmission of the virus from monkeys to
humans, resistance and genetic diversity of different types of HIV),
clinical research trials to evaluate new treatment strategies in adults,
the clinical and psychosocial impact of early multidrug therapy in
children, and opportunistic infections (cryptococcosis). Research on
viral hepatitis is also carried out onsite: studies on the prevalence
and treatment evaluations for hepatitic C. A large public health and
social sciences research program, set up at the request of the Ministry
of Health, is analyzing the political, economic, and social aspects of
upscaling and decentralization of access to antiretroviral therapy in
Cameroon, and the history of public policies for epidemic control.
\17
PARTNERS IN CAMEROON
n
n
n
n
n
n
n
n
n
n
n
Centre hospitalier de Yaoundé
Centre hospitalier de Douala
Centre Pasteur du Cameroun
Clinique de la Cathédrale (TAC)
École nationale supérieure polytechnique
Fondation Paul Ango Ela de géopolitique en Afrique centrale
Hôpital central de Yaoundé
Laboratoire mixte de l’Institut de recherches médicales et
d’études des plantes médicinales (IMPM) – Centre de recherche
sur les maladies émergentes et réémergentes (Cremer) –
Institut de recherche pour le développement (IRD)
SCAC/Ambassade de France
Université catholique d’Afrique centrale
Universités de Yaoundé I et II
PARTNERS IN FRANCE
n
n
n
n
n
n
n
n
n
Centre hospitalier universitaire de Montpellier
Centre hospitalier universitaire de Rouen
Centre national de la recherche scientifique (CNRS)
Faculté de médecine Paris-Descartes
GIP Esther (Ensemble pour une solidarité thérapeutique
hospitalière en réseau)
Institut de médecine et d’épidémiologie appliquée (IMEA)
Institut national de la santé et de la recherche médicale (Inserm)
Institut Pasteur
Institut de recherche pour le développement (IRD)
Developed world coordinator
Pr ÉRIC DELAPORTE
UMI 233 « TransVIHMI »
Centre IRD de Montpellier
911, avenue Agropolis
BP 64501
34394 Montpellier cedex 5 – France
eric.delaporte @ ird.fr
Resource-limited settings coordinator
Pr SINATA KOULLA-SHIRO
Service des maladies infectieuses
Hôpital central de Yaoundé
et faculté de médecine et des sciences
biomédicales de l’université de Yaoundé I
BP 16 237 Yaoundé – Cameroun
koullasinata @ yahoo.fr
/
18
Côte
d’Ivoire
Site PAC-CI
ANRS, Treichville
Hospital, Abidjan.
SITE
The site
Above, the Public
Health Unit, Treichville
Hospital, Abidjan.
Below, the Treatment
and Training Center
(CePReF) in Yopougon,
Abidjan.
The PAC-CI/ ANRS Côte d’Ivoire site program was set up in 1994 and
formalized in 1996 by an agreement between the Côte d’Ivoire Ministry
of Public Health, ANRS, and the French Ministry of Foreign Affairs.
This agreement set forth two goals: the training of healthcare
personnel in medical research on HIV/AIDS and the implementation
of HIV/AIDS research of interest for the general population. The
agreement was renewed in 2010 and extended to include three new
signatories: in Côte d’Ivoire, the Ministry of Higher Education and
Research, and in France, Inserm and Bordeaux Segalen University.
Within this framework there is a plan to set up an Inserm international
associated laboratory.
The Research Agency ANRS (France Recherche Nord&Sud Sida-HIV
Hépatites) has supported the establishment and equipping of
laboratories for molecular virology, parasitology, bacteriology, and
immunology, and the creation of reception facilities at several sites
in Abidjan. The ANRS has also constructed a building dedicated to
the coordination of the site’s research programs and activities, within
the grounds of the Treichville University Hospital.
Areas of research
The site's main lines of research are the improvement in care of
infected adults and amelioration of treatment of children living
with HIV.
Research on these subjects relates above all to clinical questions on
the management of HIV-positive patients at all stages of the disease:
early treatment, treatment of patients who have experienced first and
second-line treatment failure, evaluation of new drugs and strategies,
treatment of patients infected by HIV-2. A cohort of patients of known
date of infection has been in place for a number of years. Lastly, a
clinical trial on treatment of hepatitis C virus infection will start soon.
In laboratory work, studies on virus quantification and viral resistance
to antiretrovirals are prioritized.
Research is conducted by multidisciplinary teams including clinicians,
laboratory technologists, epidemiologists, statisticians, economists,
modelers, sociologists, and anthropologists.
\19
PARTNERS IN CÔTE D’IVOIRE
n
Centre hospitalier universitaire de Treichville
n
Centre hospitalier universitaire de Yopougon
n
Centre intégré de recherches biocliniques à Abidjan (CIRBA)
n
Centre national de transfusion sanguine (CNTS)
n
Centre de prise en charge et de formation (CePReF)
n
n
n
n
École nationale supérieure de statistique et d’économie appliquée
(ENSEA) d’Abidjan
Unité de soins ambulatoires et de conseil (USAC)
Université d’Abidjan-Cocody (Institut d’Ethno-sociologie,
GIRFOS-CI)
Université de Bouaké, laboratoire de sociologie
du développement
PARTNERS IN FRANCE, GERMANY, AND THE UNITED STATES
n
n
Centre hospitalier universitaire de Bordeaux
GIP Esther (Ensemble pour une solidarité thérapeutique
hospitalière en réseau)
n
Hôpital Necker, service de virologie, Paris
n
Hôpital Saint-Louis, Paris
n
Hôpital Saint-Antoine, Paris
n
Institut national de la santé et de la recherche médicale (Inserm)
n
Institut de recherche pour le développement (IRD)
n
Munich University Hospital, Germany
n
University of Harvard (CEPAC), United States
Developed world coordinator
Dr XAVIER ANGLARET
Inserm U897, Université Bordeaux Segalen
33076 Bordeaux cedex – France
xavier.anglaret @ isped.u-bordeaux2.fr
xavier.anglaret @ pacci.ci
Resource-limited settings coordinator
Pr THÉRÈSE N’DRI YOMAN
Service de gastro-entérologie, CHU de Yopougon
08 BP 412, Abidjan 08 – Côte d’Ivoire
yoman-therese.ndri @ pacci.ci
Programme PAC-CI/site ANRS
18 BP 1954, Abidjan 18 – Côte d’Ivoire
pacci @ pacci.ci
/
20
The Regional Center
for Research and
Training in HIV/AIDS
Treatment (CRCF), Fann
National University
Hospital, Dakar.
Senegal
SITE
The site
Created in 1990, the site has its foundations on a close partnership
with the National AIDS Control Committee (CNLS). Since 2005, the
creation of the Regional Center for Research and Training in HIV/AIDS
Treatment (CRCF) in the Fann National University Hospital has
facilitated the organization of clinical research, strengthened training
programs, and improved treatment of people living with HIV/AIDS.
The Research Agency ANRS (France Recherche Nord&Sud Sida-HIV
Hépatites) provides funds for infrastructure, equipment (real-time
PCR, sequencers), and staffing at the National Virology Laboratory
at the Le Dantec Hospital, and at the Fann National University Hospital
(consultation center, social services, pharmacy, analytical laboratory,
clinical trial management center, IT department, etc.).
Areas of research
Onsite research is focused in particular on clinical research:
randomized, multicenter clinical trials on antiretroviral treatment in
treatment-naive patients and antiretroviral treatment failure patients,
trials on new drugs for treatment of hepatitis C in monoinfected and
co-infected patients, and a cohort of children and adolescents infected
by HIV. In the field of social sciences and public health, ongoing studies
are considering the risk and prevention of HIV transmission, notably
in the vulnerable populations of male homosexuals and injecting drug
users, the assessment of the cost-effectiveness of second-line
treatments, the social determinants of treatment failures, the conditions
of assisted reproduction in the context of HIV infection, the experience
of treatment and its relation to gender, and the consequences of the
adverse effects of treatments.
The vegetable garden
of the Infectious
Diseases Department,
Fann National
University Hospital,
Dakar.
Following several studies of the genetic diversity of HIV and its
implications, current research in virology is focusing on resistance to
antiretrovirals and on the immunological and virological efficacy of
different therapeutic strategies.
Along with the other ANRS sites, the Senegal site is implementing in
the ANRS quality policy by recording quality indicators for clinical trials,
strengthening research ethics through community participation,
training, and respecting good clinical practice.
\21
PARTNERS IN SENEGAL
n
n
Centre hospitalier national universitaire de Fann
Centre de recherche et de formation sur la prise en
charge du VIH/sida (CRCF)
n
Hôpital Le Dantec, Dakar
n
Hôpital Principal, Dakar
n
n
Université Cheikh Anta Diop, Institut de recherche et
d’études psychopathologiques (IREP)
Université Cheikh Anta Diop, faculté de médecine
PARTNERS IN FRANCE
n
GIP Esther (Ensemble pour une solidarité thérapeutique
hospitalière en réseau)
n
Hôpital Saint-Antoine, Paris
n
Institut Pasteur
n
Institut de recherche pour le développement (IRD)
n
Institut de médecine et d’épidémiologie appliquée (IMEA)
n
Union européenne
Developed world coordinator
Dr BERNARD TAVERNE
UMI 233 « TransVIHMI »
Institut de Recherche pour le Développement (IRD)
911, avenue Agropolis
BP 64501
34394 Montpellier cedex 5 – France
bernard.taverne @ ird.fr
Resource-limited settings coordinator
Dr IBRA N’DOYE
Président du Conseil d'administration du CRCF
Centre hospitalier national universitaire de Fann
BP 45690
Dakar – Sénégal
[email protected]
[email protected]
Website : www.crcf.sn
/
22
The Institut
Pasteur of
Cambodia
in Phnom Penh.
Cambodia
SITE
The site
The ANRS site in Cambodia was officially created on 4 January 2000
through an agreement signed between the Research Agency ANRS
(France Recherche Nord&Sud Sida-HIV Hépatites), the French
Embassy, and the Cambodian Ministry of Health. The site is supported
by the Institut Pasteur of Cambodia (IPC), a member of the Institut
Pasteur international network, and the National Center for HIV/AIDS,
Dermatology and Sexually Transmitted Diseases (NCHADS). There
is a department that manages methodology and clinical research in
the Epidemiology and Public Health Unit of the IPC. The virology,
immunology, and bacteriology laboratories actively participate in
research.
The ANRS has funded diagnostic equipment and instruments for use
in research in immunology (CD4 flow cytometer, iSpot FluoroSpot
Reader), virology (MagNA Pure LC, real-time PCR), and tuberculosis
(Bactec MGIT).
Areas of research
Early research at the site focused on prevention of mother-to-child
HIV transmission. Current research is mainly clinical, with trials on
antiretroviral therapy in adults and children co-infected with HIV and
tuberculosis, mainly regarding the evaluation of diagnostic techniques
in children and, the best tuberculosis prevention and/or treatment
strategies in adults. The site is also developing basic research in
virology (viral load-genotyping of resistance to antiretrovirals) and
immunology (role of natural killer cells and T cells).
\23
PARTNERS IN CAMBODIA
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
Cambodian Health Committee (CHC)
Center for Khmer Study
La Croix Rouge française à Phnom Penh
Fondation Mérieux à Phnom Penh
Hôpital Calmette
Institut Pasteur du Cambodge
Institut de recherche pour le développement (IRD) à Phnom Penh
Kantha Bopha Hospital et Angkor Children Hospital à Siem Reap
Khmero Soviet Friendship Hospital
Kossamak Hospital
Magna
Médecins sans Frontières (France) à Phnom Penh, à Siem Reap et à Takeo
National Pediatric Hospital
Provincial Hospitals (Kompong Cham, Siem Reap, Svay Rieng, Takeo)
Royal University of Phnom Penh, department of Sociology-Anthropology
University of Health Sciences
PARTENAIRES EN FRANCE ET AUX ÉTATS-UNIS
n
n
n
n
n
n
n
n
n
n
Centre hospitalier régional universitaire Arnaud de Villeneuve, Montpellier
GIP Esther (Ensemble pour une solidarité thérapeutique hospitalière en
réseau)
Harvard Medical School, United States
Hôpital La Pitié-Salpêtrière, Paris
Hôpital du Kremlin-Bicêtre
Hôpital Necker, Paris
Institut national de la santé et de la recherche médicale (Inserm)
Institut Pasteur
Institut de recherche pour le développement (IRD)
NIH (National Institutes of Health), United States
Developed world coordinator
Dr ISABELLE FOURNIER
Inserm SC10-US019
Bâtiment 15/16
Hôpital Paul-Brousse
94807 Villejuif cedex
Isabelle.fournier @ inserm.fr
Resource-limited settings coordinator
Dr SAPHONN VONTHANAK
Deputy director of National institute of health
Chief of the Research unit of NCHADS (National Center HIV/AIDS,
Dermatology and STD)
#245H, National Road 6A, Sangkat Prek Leap
Khan Rusey Keo, Phnom Penh – Cambodia
vsaphonn @ yahoo.com
research03 @ nchads.org
/
24
The Institut
Pasteur in Ho
Chi Minh City.
Vietnam
SITE
The site
Relations between teams of French and Vietnamese researchers
started in 1988. A first collaboration agreement was signed in 1995,
and then, on 6 January 2000, the ANRS site of Vietnam was officially
created.
Most of the studies funded by the Research Agency ANRS (France
Recherche Nord&Sud Sida-HIV Hépatites) are conducted in Ho Chi
Minh City, with the support of the Institut Pasteur and the city’s
hospitals, with in the framework of national (VAAC) and provincial
(PAC) AIDS control programs. The studies now extend to the north
of Vietnam, notably Hanoi and Hai Phong. The work is conducted by
teams of clinicians, virologists, microbiologists, immunologists, and
human and social science researchers.
Above, the Pham Ngoc
Thach Hospital in Ho
Chi Minh City.
Below, brochure
published for the tenth
anniversary of the
ANRS-Southeast Asia
collaboration.
Areas of research
The site's research activity began with projects focusing on virology
(genetic variability) and molecular epidemiology (resistance to
antiretrovirals). Clinical research has mainly focused on the treatment
of adults co-infected with HIV and tuberculosis. One of two
complementary trials on HIV/tuberculosis co-infection will explore
the routine empirical treatment of tuberculosis before initiation of
antiretroviral treatment, in HIV-infected patients. The other trial will
study an alternative antiretroviral strategy in the patients co-infected
with HIV and tuberculosis. Work is also being conducted on the question
of HIV/tuberculosis co-infection in children, focusing on the evaluation
of different methods of diagnosing tuberculosis. A pilot study of the
treatment of patients infected by the hepatitis C virus is also planned.
The ANRS has equipped the site with real-time PCR apparatus and
has developed a method suited to the strains circulating in Asia.
Multidisciplinary research supporting the Vietnamese government’s
initiative to reduce the risk of HIV infection among intravenous drugs
users is mainly investigating the characteristics and outcomes of
HIV and hepatitis infected patients.
\25
PARTNERS IN VIETNAM
n
Children’s Hospital no. 1 (Nhi Dong 1)
n
Children’s Hospital no. 2 (Nhi Dong 2)
n
The Hospital for Tropical Diseases
n
Institut Pasteur in Ho Chi Minh City
n
Institute for Population and Social Studies, National Economics
University
n
National Hospital of Pediatrics
n
Pham Ngoc Thach Hospital
n
Provincial AIDS Committees (PAC)
n
Vietnamese Academy of Social Sciences, Southern Institute of Social
Sciences
PARTNERS IN FRANCE
n
GIP Esther (Ensemble pour une solidarité thérapeutique hospitalière
en réseau)
n
Hôpital européen Georges-Pompidou à Paris
n
Hôpital Henri Mondor, Créteil
n
Hôpital du Kremlin-Bicêtre
n
Hôpital Necker, Paris
n
Hôpital Saint-Antoine, Paris
n
Institut national de la santé et de la recherche médicale (Inserm)
n
International Union Against Tuberculosis and Lung Disease (IUATLD)
Developed world coordinator
Pr FRANÇOISE BARRÉ-SINOUSSI
Institut Pasteur
Département de virologie
Unité de régulation des infections rétrovirales
25, rue du Docteur-Roux
75724 Paris cedex 15 – France
fbarre @ pasteur.fr
Resource-limited settings coordinator
Dr TRUONG XUAN LIEN
Institut Pasteur de Hô Chi Minh Ville
167, rue Pasteur, 3 e Arr.
Hô Chi Minh Ville – Vietnam
truongxuanlien @ gmail.com
/
26
Egypt
SITE
The Imbaba
Fever Hospital
in Cairo.
The site
A multidisciplinary French-Egyptian network including the Pasteur
Institute in Paris and several research institutions and universities
in Cairo has been working on hepatitis C in Egypt since 2001. This
collaboration led to the creation of the ANRS site in 2007. Research
work is organized around two study sites: a cohort in a rural setting,
at Zawiat Razin, and two “fever hospitals” in Cairo.
The Research Agency ANRS (France Recherche Nord&Sud Sida-HIV
Hépatites) has helped equip clinical research facilities in the Medical
Faculty of Ain Shams University.
Below, the Medical
Faculty, Ain Shams
University, Cairo.
The site’s research work has helped in the drawing up of a national
strategy for the control of the epidemic in Egypt. Four of the six
members of the National Viral Hepatitis Committee belong to the
research network, thus expediting the transfer and use of scientific
data in the creation of national policies.
Areas of research
The site’s programs are devoted to basic, clinical and epidemiological
research on hepatitis C. The main research objectives are estimation
of the prevalence of hepatitis C infection, identification of infection
risk factors, optimization of drug regimens in the treatment of acute
and chronic hepatitis C, and, with a view on vaccine development,
understanding the spontaneous elimination of the virus during the
acute phase of the infection.
\27
PARTNERS IN EGYPT
n
Ain Shams University, Faculty of Medicine
n
Mansoura University
n
National Hepatology and Tropical Medicine Research
Institute (NHTMRI)
PARTNERS IN FRANCE
n
Institut national de la santé et de la recherche
médicale (Inserm)
n
Institut Pasteur de Paris
n
Hôpital Beaujon, Clichy
n
Hôpital Bichat-Claude Bernard, Paris
n
Hôpital Cochin, Paris
n
Hôpital Gustave-Dron, Tourcoing
n
Hôpital du Kremlin-Bicêtre
n
Hôpital Purpan, Toulouse
n
Hôpital Tenon, Paris
Developed world coordinator
Pr ARNAUD FONTANET
Institut Pasteur
Unité d’épidémiologie des maladies émergentes
28, rue du Docteur-Roux
75015 Paris – France
fontanet @ pasteur.fr
Resource-limited settings coordinator
Pr GAMAL ESMAT
The Ministry of Health and Population
National Hepatology and Tropical Medicine
Research Institute (NHTMRI)
10 Kasr El Aini street, Cairo, Egypt
g_esmat @ yahoo.com
Website: www.hepnile.org
/
28
Brazil
SITE
The Evandro Chagas
Institute for Clinical
Research (IPEC),
Fiocruz, Rio de
Janeiro.
The site
In July 2001, the Research Agency ANRS (France Recherche
Nord&Sud Sida-HIV Hépatites) and the Brazilian Ministry of Health
signed a protocol for collaboration with the aim of setting up a
partnership between Brazilian and French teams. There is no physical
site in Brazil, but rather a French-Brazilian collaborative program.
Above, the head office
of Fiocruz in Rio de
Janeiro.
Below, brochure
published for the tenth
anniversary of the
ANRS-Brazil
collaboration.
Brazil is one of the resource-limited countries that has implemented
the widest-ranging policy for access to antiretroviral treatments.
This policy is based on experience and know-how on the production
of generic drugs, and on industrial production capacity, which are
the subjects of ongoing research.
Areas of research
The site’s work focuses mainly on prevention and on socioeconomic
research on health and access to treatment, with programs on access
to antiretrovirals, drug policy and intellectual property, technology
transfer, analysis of public policies, and vulnerable populations (transand homosexuals).
The site’s clinical research has taken shape through the establishment
of a clinical trial on the treatment of HIV/tuberculosis co-infection.
Work also focuses on viral hepatitis through a program designed to
characterize hepatitis viruses circulating in Amazonia and their impact
on liver disease.
\29
PARTNERS IN BRAZIL
n
Centro de Referência e Treinamento DST/Aids, São Paulo
n
Escola Nacional de Saúde Publica Sergo Arouca
n
Hospital Universitário-HUPES, Salvador
n
n
n
n
Instituto de Economia, Universidade Federal do Rio de Janeiro
(UFRJ)
Instituto de Medicina Social, Universidade do Estado do Rio de
Janeiro (UERJ)
Instituto Oswaldo Cruz/IPEC/Laboratório Virtual de Inovação e
Propriedade Intelectual em Saúde, Fiocruz, Rio de Janeiro
Universidade Federal do Ceará
PARTNERS IN FRANCE AND OTHER COUNTRIES
n
Gujarat Institute of Development Research, Ahmedabad, India
n
Hôpital Saint-Louis, Paris
n
Institut national de la santé et de la recherche médicale (Inserm)
n
Institut Pasteur
n
Institut de recherche pour le développement (IRD)
n
Jawaharlal Nehru University, New Delhi, India
n
Tulane University, New Orleans, United States
n
Université Paris-Nord, centre d’économie (CEPN)
n
Université du Québec à Rimouski (UQAR), Canada
Developed world coordinator
Dr BERNARD LAROUZÉ
UMRS 1136
Faculté de médecine Pierre et Marie Curie – pôle Saint-Antoine
27, rue de Chaligny
76571 Paris cedex 12 – France
larouze @ u707.jussieu.fr
Resource-limited setting coordinator
CRISTINA PIMENTA
Departamento de DST, AIDS e Hepatites Virais
Ministério da Saúde
Setor de Administração Federal Sul 2, Lote 5/6,
Bloco F, Torre 1 – Edifício Premium, Asa Sul,
70 070-600, Brasília/DF – Brasil
Cpimienta48 @ gmail.com
/
30
Ongoing Projects
N° ANRS/
Reference
Project Coordinators
Project title
Country
HIV INFECTION
Basic science and physiopathology
Immunological and virological infection factors
ANRS 12193
Édouard TUAILLON
Diane VALEA
Immune activation and impact of HSV suppressive therapy on genital and
systemic HIV-1 replication (ANRS 1285 trial)
Burkina Faso
ANRS 12205
Nicolas NAGOT
Diane VALEA
Biological mechanisms underlying the impact of HSV suppressive therapy on
genital and plasma HIV-1 replication
Burkina Faso
ANRS 12207
PRIVAR
Michèle FEVRIER
Anfumbom Jude KFUTWAH
Analysis of cell-mediated immune response to measles vaccine in HIV-infected
infants in Cameroon
Cameroon
ANRS 12255
Martine PEETERS
Eitel MPOUDI-NGOLE
Identification and risk assessment of additional SIV transmissions from wild living Cameroon, Gabon,
primate populations to humans and thorough exploration of the HIV-1 reservoir
Democratic Republic of
ancestors in the great apes from West Central Africa
Congo
Inter-species Transmission
Descriptive Epidemiology
Molecular Epidemiology
ANRS 12256
RECAMO
Jean-Christophe PLANTIER
Anfumbom Jude KFUTWAH
Prevalence and virological characterization of dual HIV-1 M and HIV-1 O
Cameroon
infections and HIV-1 M+O recombinants forms associated or not to dual infection
circulating in Cameroon
ANRS 12281
CI
Jean-Christophe PLANTIER
Sandrine MOUSSA
Molecular epidemiology of HIV-1 group O, and other variants non-M circulating in Central African Republic
Central African Republic from 2003 to 2011
ANRS 12204
DYTRAVIHT
Sylvain GODREUIL
Hervé HIEN
Tuberculosis-HIV co-infections
Impact of HIV Mycobacteruim tuberculosis co-infection on the dynamics of
tuberculosis transmission in Burkina Faso
ANRS 12274
Daniel SCOTT-ALGARA
Mariza MORGADO
Characterization of innate immunity and biomarkers in tuberculosis/HIV coinfected patients
Brazil
ANRS 12278
Sylvain GODREUIL
Didier LAUREILLARD
Effect of Mycobacterium tuberculosis genetics on clinical outcomes of
HIV/tuberculosis co-infected adults enrolled in the CAMELIA (ANRS 1295/CIPRA
KH001) trial
Cambodia
ANRS 12310
TBMACA
Marie-Catherine RECEVEUR
Serge DOMOUA
Prevalence study of tuberculosis and drug susceptibility among detainees at the Côte d’Ivoire
MACA prison in Côte d’Ivoire, in a high HIV prevalence contex
Burkina Faso
Clinical research
Clinical trials
ANRS 12174
PROMISE-PEP
Philippe VAN DE PERRE
Nicolas MEDA
Prevention of Mother to Child Transmission
A randomiszed controlled trial comparing the efficacy of infant peri-exposure
prophylaxis with Lopinabvir/Ritonavir versus Lamivudine to prevent HIV-1
transmission by breastfeeding (South Africa, Burkina Faso, Uganda, Zambia)
ANRS 12136
TEMPRANO
Xavier ANGLARET
Serge EHOLIE
Care by antiretroviral therapy in adults
Randomised trial of Izoniazide chemoprophylaxis against tuberculosis, earlier
antiretroviral treatment, or both, in HIV-infected adults with CD4 between 250
and 500/mm3
ANRS 12168
DYNA M-O
Jean-Christophe PLANTIER
Charles KOUANFACK
HIV-1 group O strains molecular diversity and therapeutic management in
Cameroon
South Africa, Burkina Faso,
Uganda, Zambia
Côte d’Ivoire
Cameroon
\31
[
more at www.anrs.fr
]
N° ANRS/
Reference
Project Coordinators
Project title
Country
ANRS 12169
2-LADY
Eric DELAPORTE
Sinata KOULLA SHIRO
Non inferiority randomized open phase III clinical trial comparing the virological
efficacy and safety of three second line antiretroviral regimens during 48 weeks
in HIV infected patients in Cameroon and Senegal
Burkina Faso, Cameroon,
Senegal
ANRS 12237
FATI
Christine DANEL
Serge EHOLIE
Fozivudine in Africa Trials Initiative (FATI) - Phase II trial
Côte d’Ivoire
ANRS 12269
THILAO
Roland LANDMAN
Serge EHOLIE
Strengthening of medication compliance and treatment with Darunavir and
Raltegravir in adults infected with HIV-1 in virologic failure of second line
antiretroviral therapy in Sub-Saharan Africa
Burkina Faso, Côte d’Ivoire,
Mali, Senegal
ANRS 12286
MOBIDIP
Laura CIAFFI
Sinata KOULLA SHIRO
Evaluation of a maintenance strategy with Protease Inhibitors with or without
Lamivudine in virologically controlled HIV patients on second line antiretroviral
treatment in Africa (Dakar, Bobo Dioulasso, Yaounde)
Burkina Faso, Cameroon,
Senegal
ANRS 12294
FIT2
Françoise BRUN-VEZINET
Serge EHOLIE
Tolerance and efficacy of four antiretroviral therapy with Tenofovir-Emtricitabine Burkina Faso, Côte d’Ivoire,
plus Lopinavir/Ritonavir, or Raltegravir or Elvitegravir-Cobicistat among adults Guinea, Senegal, Togo
HIV-2 infected patients in West Africa. A multicountry and multicenter, phase IIb
randomized controlled trial
ANRS 12313
NAMSAL
Pierre DE BEAUDRAP
Charles KOUANFACK
A phase III randomized, open label trial to evaluate Pending Dolutegravir +
Burkina Faso
Lamuvidine + Abacavir versus Efavirenz +Emtricitabine + Tenofovir as part of two Cameroon
treatment sequences for the initial management of HIV infected adults in
resource-limited settings (NAMSAL)
ANRS 12206
MONOD
Valériane LEROY
Marguerite TIMITE
Antiretroviral therapy in children
Randomized phase 2b trial for evaluation of simplified "once a day"
antiretroviral strategy in children infected by HIV and under antiretroviral
systematic therapy before one year of age
ANRS 12180
REFLATE TB
Jean-Michel MOLINA
Beatriz GRINSZTEJN
Tuberculosis-HIV co-infections
A phase II randomized multicenter trial to compare the efficacy and safety of two Brazil
doses of Raltegravir or Efavirenz in combination with Tenofovir and Emtricitabine,
in naive HIV-infected patients receiving Rifampin for active tuberculosis
ANRS 12290
STATIS
François-Xavier BLANC
Serge DOMOUA
Systematic empirical versus test-guided anti-tuberculosis treatment impact in Cambodia, Côte d’Ivoire,
severely immunosuppressed HIV-infected adults initiating antiretroviral therapy Uganda, Vietnam
with CD4 cell counts < 100/mm3
ANRS 12292
RIFAVIRENZ
Maryline BONNET
Daniel ATWINE
Interaction between high dose Rifampicin and Efavirenz in pulmonary
tuberculosis and HIV co-infection
ANRS 12300
REFLATE TB2
Nathalie DE CASTRO
Beatriz GRINSZTEJN
Phase III open-label non inferiority randomized multicenter trial to assess the Brazil, Côte d’Ivoire,
non-inferiority of Raltegravir versus Efavirenz, both in combination with
Vietnam
Tenofovir and Lamivudine in naive HIV-1 infected patients receiving Rifampin for
active tuberculosis
ANRS 12257
FLUCOCRYPTO
Olivier BOUCHAUD
Théodore NIYONGABO
ANRS 12275
ACTA
Olivier LORTHOLARY
Charles KOUANFACK
Opportunistic Infections
Prospective pilot study evaluating efficiency and tolerance of high-dose
Fluconazole associated with Flucytosine as induction therapy for Cryptococcal
meningitis associated with HIV in Burundi
A phase III randomised controlled trial of oral Fluconazole plus Flucytosine
versus AmB-based therapy for one or two weeks for initial treatment of HIVassociated cryptococcal meningitis
Burkina Faso, Côte d’Ivoire
Uganda
Burundi, Côte d’Ivoire
Cameroon, Malawi, Zambia
Diagnostic and Biological follow-up
ANRS 12250
METABODY
Laura CIAFFI
Assane DIOUF
Assessment of lipodystrophy and metabolic disorders in patients on second line
antiretroviral treatment in Africa (Bobo Dioulasso, Dakar, Yaounde) : study
associated to clinical trial 2-LADY (ANRS 12169)
Burkina Faso,
Cameroon, Senegal
ANRS 12253
TEMPRANO
Résistance
Christine DANEL
Thomas d’Aquin TONI
Impact of the CD4 stage when starting ART on the medium-term viral resistances Côte d’Ivoire
in adults in Côte d’Ivoire
/
32
Ongoing Projects
N° ANRS/
Reference
Project Coordinators
Project title
Country
ANRS 12273
Marie-Laure CHAIX
Eugène MESSOU
Virological failure and HIV-1 resistance to antiretroviral drugs at 36, 48, 60 and 72
Côte d’Ivoire
months of treatment: a cohort study in HIV-1 infected adults in Abidjan, Côte d’Ivoire
ANRS 12276
2PICAM
Eric NERRIENET
Vonthanak SAPHONN
National evaluation of PI-based 2nd line efficacy in Cambodia
Cambodia
ANRS 12301
VIH-2 Viro
Jean-Christophe PLANTIER
Thomas d’Aquin TONI
Molecular diagnosis of HIV-2 and dual HIV-1 + 2 infections in western Africa
Burkina Faso, Cameroon,
Côte d’Ivoire, Mali
ANRS 12229
PAANTHER01
Olivier MARCY
Vibol UNG
Tuberculosis-HIV co-infections
Improving diagnosis of Tuberculosis in HIV infected children in Asia (Cambodia,
Vietnam) and in Africa (Burkina Faso, Cameroon)
ANRS 12293
PROMISE-TB
Edouard TUAILLON
Chipepo KANKASA
PROMoting Infant health and nutrition in Sub-Saharan Africa - Evaluation of
Innovative TuBerculosis diagnostic tests (PROMISE-TB)
ANRS 12260
EDIRAPHIS
Mathieu NACHER
Stephen VREDEN
Opportunistic infections
Histoplasmosis due to Histoplasma capsulatum var. capsulatum in the Guiana
Shield and the French West Indies: evaluating prevalence in HIV-infected
patients with a rapid diagnostic test using an ELISA capture method for the
detection of histoplasma antigens in blood and urine
ANRS 12312
PreCASA
Olivier LORTHOLARY
DEFO
Burkina Faso, Cambodia,
Cameroon, Vietnam
Zambia
Suriname
Cryptococcal antigen screening, management and outcome in HIV infected
Cameroon
patients initiating antiretroviral therapy with less than 100 CD4 cell count at the
day hospital of the Yaounde Central Hospital, Cameroon: a prospective study
Cohorts
ANRS 12277
Charlotte LEWDEN
PRECO-CI
Albert MINGA
(following the
cohort ANRS 1220
PRIMO-CI)
Care by antiretroviral therapy in adults
Research platform « Early identification and treatment of early HIV infection in
Côte d’Ivoire »
Côte d’Ivoire
Cameroon
ANRS 12225
PEDIACAM II
Albert FAYE
Mathurin Cyrille TEJIOKEM
Care by antiretroviral therapy in children
Outcome at 5 years of early treated HIV infected infants with antiretroviral multitherapy in the Pediacam ANRS 12140 project Cameroon
ANRS 12279
MAGGSEN
Philippe MSELLATI
Haby SY SIGNATE
Growing up with HIV in Senegal (Risk factors for nutritional and metabolic
disorders in children and adolescents on antiretroviral therapy or not)
Senegal
Socio-behavioural Sciences and Public Health
Public Policy Analysis
ANRS 12211
Maurice CASSIER
Marilena CORDEIRO DIAS
VILLELA CORREA
The new implications of the production of second-line ARVs in Brazil: Using the
flexibilities of patent law and producing certified generic drugs
Brazil
ANRS 12288
EVOLCAM
Laurent VIDAL
Christopher KUABAN
Analysis of the Cameroonian ART program evolutions regarding the new issues of Cameroon
HIV care and HIV-related co-infections in the centre and littoral regions
ANRS 12315
Fred EBOKO
Maurice ENGUELEGUELE
AIDS and Governance in Africa: understanding and reinforcing the action of
country-coordinating mechanisms. A comparative study between Senegal, Côte
d’Ivoire and Cameroon
Cameroon, Côte d’Ivoire,
Senegal
Health Economics
ANRS 12162
Benjamin CORIAT
Lia HASENCLEVER
Production and procurement of generic ARVs in the context of the post 2005
TRIPS agenda
Brazil, India
ANRS 12213
Fabienne ORSI
Claudia CHAMAS
Clinical data, bioequivalence and generic drugs. Analysis from India and Brazil
Brazil, India
\33
[
more at www.anrs.fr
]
N° ANRS/
Reference
Project Coordinators
Project title
Country
ANRS 12231
2LADY-SHS
Bruno SPIRE
Papa Salif SOW
Cost-effectivness analysis of three second-line antiretroviral treatment
Burkina Faso, Cameroon,
strategies in Africa: research project associated to the ANRS 12169 2-LADY trial Senegal
ANRS 12254
Arnousse BEAULIERE
Yaya COULIBALY
Non-antiretroviral drugs for HIV-infected adults: quality of prescriptions, cost
and cost-effectivness in Côte d’Ivoire
Côte d’Ivoire
ANRS 12264
CI
Benjamin CORIAT
Access to HIV viral load in resource-limited settings: market and procurement
policies analysis in three countries
Brazil, Cameroon, Senegal
ANRS 12305
CI
David GOEURY
Hakima HIMMICH
Microcredit and people living with HIV, spatial analysis in five African countries
Morocco
Prevention
General population
Evaluation of the extension at community level of safe male circumcision
ANRS 12126
ORANGE FARM 2
Bertran AUVERT
Dirk TALJAARD
South Africa
ANRS 12249
TasP
François DABIS
Marie-Louise NEWELL
A cluster randomised trial comparing the impact of immediate versus WHO
recommendations guided ART initiation on HIV incidence in Hlabisa sub-district,
KwaZulu-Natal, South Africa
South Africa
ANRS 12285
Bertran AUVERT
Adrian PUREN
Roll-out of voluntary medical male circumcision in Orange Farm (South Africa):
effect on HIV incidence among men
South Africa
ANRS 12189
François FAVIER
Abdramane BERTHE
Women, children and mother to child transmission
Action research for the prevention of the HIV-AIDS in Madagascar, Burkina Faso
and Cameroon: study of the impact in population of the FMFP program "sexual
risks reduction" in women based on the formation of trainers within a global
approach of sexuality in a community health type process
ANRS 12228
Marc-Eric GRUENAIS
Tinoga Laurent OUEDRAOGO
Access to maternal/infantile healthcare and follow up of women infected by the Burkina Faso
HIV/AIDS in Burkina Faso. A multidisciplinary initiative to reduce the
transmission of the virus from mother to child
ANRS 12271
Alice DESCLAUX
Khoudia SOW
Infants protected by antiretroviral treatments. Ethnological and compared
analysis (Senegal, Burkina Faso, Laos)
Burkina Faso, Laos, Senegal
ANRS 12316
Frédéric LE MARCIS
Fernand BATIONO
Spatial inequality, mobility and exclusive breastfeeding with prophylaxy
experience in Burkina Faso: an anthropological and geographical analysis to
better understand the constraints of secure breastfeeding
Burkina Faso
Burkina Faso, Cameroon,
Madagascar
Key populations
ANRS 12280
CohMSM
CI
Christian LAURENT
Yves YOMB
Prevention of HIV infection in men who have sex with men in Sub-Saharan Africa: Burkina Faso, Cameroon,
a feasibility study of an incident multicentric cohort
Côte d’Ivoire, Mali, Senegal
ANRS 12302
HANDIVIH
Pierre DE BEAUDRAP
Gervais BENINGUISSE
Disability and HIV: an appraisal of the vulnerability of disabled people to HIV
infection in three main cities of Sub-Saharan Africa
ANRS 12304
CI
Alain GIAMI
Sergio CARRARA
Health and citizenship among Trans individuals in Brazil: a comparative approach Brazil
(Pilot study)
ANRS 12272
Christine SALOMON
Marie-Francke PURUEHNCE
Age relationships, gender and social change: the impact on HIV testing and care Republic of the Congo
in Pointe Noire (Republic of Congo)
Burkina Faso
Cameroon
Screening
Living with the disease
General population
ANRS 12239
Annabel DESGRÉES DU LOU
TEMPRANO Social Raïmi FASSASSI
Social and behavioural impact of very early anti-retroviral treatment within the
TEMPRANO trial, Côte d’Ivoire
Côte d’Ivoire
/
34
Ongoing Projects
N° ANRS/
Reference
Project Coordinators
Project title
Country
Women, children and mother to child transmission
ANRS 12177
Fred EBOKO
Claude ABE
Socio-anthropological study: monitoring of HIV-1 infected infants under early
anti-retroviral treatment in Cameroon
Cameroon
ANRS 12238
ADOLIANCE
Philippe DELMAS
Eliana GALANO
Psychosocial factors associated with antiretroviral adherence and living
experience of adolescents living with HIV in São Paulo Brazil
Brazil
Other research areas
ANRS 12242
Frédéric LE MARCIS
Mariatou KONE
The Clinical trial as a space of encounter. From scientific logics to individual
experiences: construction of participant, biosociality and experience of
subjectivation
ANRS 12314
Pierre-Yves BOELLE
André PERISSE
Sexual networks in HIV infection among MSM: observation, analysis and
comparative modeling in Brazil and France
Côte d’Ivoire
Key population
Brazil
Co-infection HIV/hepatitis viruses
Basic Science and Physiopathology
Immunological and Virological infection factors
ANRS 12296
CI
Philippe MOREAU
Eduardo DONADI
Influence of the expression of the immunoregulatory molecule HLA-G in the
infection of hepatitis C virus and co-infection HIV/HCV
Brazil
Descriptive Epidemiology
Clinical Epidemiology
ANRS 12240
VarBva
Karine LACOMBE
Raoul MOH
Genetic variability of HBV in the context of HIV infection in Africa: the VarBvA
study
Côte d’Ivoire
Clinical Research
Clinical Epidemiology
ANRS 12262
CI
Maud LEMOINE
Chau NGUYEN VAN VINH
HIV-Hepatitis C co-infection in Vietnam: feasability study of a PegVietnam
Interferon/Ribavirin therapy in HIV-HCV co-infected patients living in Ho Chi Minh
City
Social-behavioural Sciences and Public Health
Prevention
ANRS 12299
DRIVE-IN
Nicolas NAGOT
Huong DUONG THI
Key population
DRIVE project: DRugs and viral Infections in Viet Nam DRIVE-IN: DRIVE Feasibility Vietnam
project,
Screening
ANRS 12287
DOD-CI
Joseph LARMARANGE
Christine DANEL
Demand and supply of HIV and viral hepatitis B and C testing in Côte d’Ivoire pilot Côte d’Ivoire
phase
Hepatitis viruses infection
Descriptive Epidemiology
ANRS 12295
François DABIS
Maïa BUTSASHVILI
Framing potential research in the area of immunogenetic, viral and behavioral
risk factors of clinical course of HCV infection in Georgia
Georgia
CI
Immunological and Virological infection factors
ANRS 12263
CI
Caroline BESSON
Characterisation of hepatitis related lymphomas in Mansoura region (Egypt)
Hasan Ahmed ABD EL-GHAFFAR
Egypt
\35
[
more at www.anrs.fr
N° ANRS/
Reference
Project Coordinators
]
Project title
Country
Molecular Epidemiology
ANRS 12202
Paul DENY
Narcisse KOMAS
Delta and B viral hepatitis in Central Africa Republic
Central African Republic
ANRS 12270
Pierre DUJOLS
Yacouba NEBIE
Epidemiology of hepatitis B and C virus infections nested in a nation-wide
population survey in Burkina Faso
Burkina Faso
ANRS 12289
Arnaud FONTANET
Richard NJOUOM
Epidemiology of viral hepatitis B, C, and delta in Cameroon: analysis of samples Cameroon
collected during the 2011 demographic health survey
Clinical Epidemiology
ANRS 12191
COPEHEBO
Philippe MSELLATI
Boubacar NACRO
Clinical and biological evolution of a cohort of children with a chronic hepatitis B Burkina Faso
infection in Bobo Dioulasso, Burkina Faso
ANRS 12259
Christian TREPO
Raymundo PARANA
Hepatitis B and D viruses in Brazilian Amazonia: analysis of the specific viral
genotypes or mutant viruses whose interactions modulate the severity of liver
disease
Brazil
Clinical Research
Clinical Trials
ANRS 12226
ViZIR
Arnaud FONTANET
Gamal ESMAT
ANRS 12311
TAC
Karine LACOMBE
Alain ATTIA
Efficacy and safety of the combination vitamin D, with Pegylated Interferon
Egypt
α2b/Ribavirin in Egyptian patients with untreated chronic hepatitis C: A phase III
randomized open-label clinical trial
Feasibility, tolerability and efficacy of a 24-week course of Peg-Interferon free
treatment with Sofosbuvir and Ribavirin in HCV-genotype 1 and 4 infected
patients in West and Central Africa
Cameroon, Côte d’Ivoire,
Senegal
Diagnostic and Biological follow-up
ANRS 12184
Philippe BONNARD
Gamal ESMAT
Liver fibrosis evaluation among HCV genotype 4 infected patients in Egypt.
Comparison of elastometry, histology and serum markers
Egypt
ANRS 12187
Marie-Laure CHAIX
Diane VALEA
Validation and transfer in Burkina Faso of a real-time PCR technique for the HBV Burkina Faso
DNA detection/quantification
ANRS 12210
Arnaud FONTANET
Mohsen GADALLAH
Prospective, multicentered, open cohort of symptomatic acute hepatitis B and C Egypt
in Egypt (continuation of project ANRS 12122)
ANRS 12291
Arnaud FONTANET
Wahid DOSS
Evaluation of the national treatment program of hepatitis C in Egypt, using data
coming from two treatment centres
Cohorts
Public Policies Analysis
Egypt
Prevention
Women, children and mother to child transmission
ANRS 12303
Françoise LUNEL-FABIANI
Richard NJOUOM
Evaluation of the effectiveness of hepatitis B vaccination of newborns from
HBsAg HBe Ag-positive mothers followed by the national enlarged vaccination
program including HB in the district health of Tokomberes, Cameroon
Cameroon
Socio-behavioural Sciences and Public Health
Prevention
ANRS 12258
General population
Tamara GILES-VERNICK TRAORE A socio-cultural analysis of hepatitis B “disease” and vaccination for HVB in two Burkina Faso
different contexts: Burkina Faso and Central African Republic
Central African Republic
[
more at www.anrs.fr
]
Photographs: Dora Bazin - page 2. Brigitte Bazin - pages 4, 5, 7, 8, 9 (top), 16 (bottom), 18 (middle and
bottom), 20 (bottom), 21. Geraldine Colin - page 18 (top). Celine Lallemand - page 22 (top and middle)
and 24 (top and middle). Claire Rekacewicz - page 26 (top). Laurence Quinty - cover and pages 6, 14,
16 (top and middle), 20, 26, 28. Michel Hasson - pages 17, 19.
© IRD: Cheik Sokhna, Cécile Neel - page 8. Justine Montmarche - page 10. Luce Arnaud - page 15.
Stéphanie Carrière page 23. Monteroi - page 25. Corinne Schwartz - page 27. Pierre Gazin - page 29.
Graphic design: Isabelle Benoit. Document designed and produced Research in Resource-limited
Settings Department and Scientific Information and Communication Department of the ANRS. 101, rue
de Tolbiac - 75013 Paris © Mars 2014

Download Report